問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center (在職)

Division of Rheumatology

Division of General Internal Medicine

Chi Mei Medical Center (在職)

更新時間：2023-09-19

林永章
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

20Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林永章

List

35Cases

2025-06-01 - 2029-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-06-16 - 2026-07-31

Phase III

Active
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel- group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy

  • Condition/Disease

    moderate-to-severe systemic lupus erythematosus (SLE)

  • Test Drug

    tablet

Participate Sites
11Sites

Not yet recruiting1Sites

Recruiting10Sites

2023-12-26 - 2026-05-14

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2025-12-22 - 2028-10-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2009-11-01 - 2012-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2024-12-20 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-01-03 - 2029-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2011-05-01 - 2013-05-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2022-12-14 - 2026-12-31

Phase III

Active
A Multi-center, Randomized, Double-blind, Active-controlled, Therapeutic Confirmatory, Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout Patients

  • Condition/Disease

    Gout

  • Test Drug

    錠劑

Participate Sites
13Sites

Recruiting13Sites

2025-02-28 - 2028-08-30

Phase III

Active
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)

  • Condition/Disease

    Psoriatic Arthritis

  • Test Drug

    N/A Hard empty capsules

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB